What is Wedbush’s Forecast for PepGen FY2025 Earnings?

PepGen, Inc. (NASDAQ:PEPG) – Equities research analysts at Wedbush lifted their FY2025 EPS estimates for shares of PepGen in a research note issued on Wednesday, November 12th. Wedbush analyst L. Chico now anticipates that the company will earn ($2.25) per share for the year, up from their previous forecast of ($2.44). Wedbush has a “Outperform” rating and a $9.00 price target on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. Wedbush also issued estimates for PepGen’s Q4 2025 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.32) EPS, FY2027 earnings at ($1.21) EPS and FY2028 earnings at ($1.18) EPS.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.11.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright boosted their price target on shares of PepGen from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday. Guggenheim reiterated a “buy” rating and set a $6.00 target price on shares of PepGen in a research report on Wednesday, September 24th. Stifel Nicolaus boosted their target price on PepGen from $9.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of PepGen in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded PepGen from a “sell” rating to a “hold” rating in a research note on Saturday. Four analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, PepGen currently has a consensus rating of “Hold” and a consensus target price of $10.00.

PepGen Stock Performance

PEPG opened at $4.74 on Monday. PepGen has a one year low of $0.88 and a one year high of $6.85. The company has a market cap of $155.47 million, a P/E ratio of -1.68 and a beta of 1.95. The business’s 50-day simple moving average is $4.00 and its 200-day simple moving average is $2.29.

Insiders Place Their Bets

In other PepGen news, major shareholder Science Enterprises Plc Oxford purchased 200,000 shares of the stock in a transaction dated Tuesday, September 30th. The shares were acquired at an average cost of $3.20 per share, for a total transaction of $640,000.00. Following the completion of the transaction, the insider directly owned 4,955,388 shares of the company’s stock, valued at $15,857,241.60. This trade represents a 4.21% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in shares of PepGen during the 1st quarter worth about $25,000. ADAR1 Capital Management LLC purchased a new position in PepGen in the first quarter valued at approximately $29,000. Rangeley Capital LLC lifted its position in PepGen by 133.3% during the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock valued at $39,000 after buying an additional 20,000 shares in the last quarter. Marshall Wace LLP acquired a new position in PepGen during the second quarter valued at approximately $44,000. Finally, Burkehill Global Management LP purchased a new stake in PepGen during the third quarter worth approximately $46,000. 58.01% of the stock is currently owned by hedge funds and other institutional investors.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.